COMP <GO>
HAE vs UNH // 10Y YIELD & FRED MACRO BETA
Haemonetics Corporation (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: HAE 4
— UNH 10
▲ 10Y YIELD & FRED MACRO BETA LEADER: HAE
LAST: $119.65 (-0.12%) • MKT CAP: $5.45B
macro-sensitivity
1.00
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
macro-sensitivity
0.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HAE VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HAE | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.00% | 88.57% | -29.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.40% | 11.47% | -3.07 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 32.5x | 16.4x | +16.05 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 4.78% | 6.48% | -1.70 | UNH | /fcf-yield <GO> |
| Operating Margin | 11.70% | 4.82% | +6.88 | HAE | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 3.14% | -3.14 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | -2.00% | 6.46% | -8.46 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.89 | 3.12 | +0.77 | HAE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.74% | +0.16 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.3 | 56.0 | +7.22 | HAE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.00 | 0.33 | +0.67 | HAE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 17.1x | +122.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.45B | $364.66B | -$359.21B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HAE REV | UNH REV | HAE GROSS % | UNH GROSS % | HAE FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.33B | $447.57B | 59.0% | 88.7% | $260.4M | $16.07B |
| FY 2024 | $1.36B | $400.28B | 55.0% | 88.3% | $142.4M | $20.70B |
| FY 2023 | $1.31B | $371.62B | 44.0% | 89.6% | $122.8M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HAE // BETA 1.00
UNH // BETA 0.33